Partners study expands our knowledge of HIV transmission risk
Modellers examine the cost-effectiveness of PrEP in Africa
Forecasters agree PrEP/microbicides could cut HIV infections in South Africa
Once-daily raltegravir found inferior to twice-daily dosing
Is HIV drug resistance spreading? Early warning signals say 'yes'
Telaprevir works well for people with HIV/HCV co-infection
First pills-versus-gel trial finds US women prefer oral PrEP
Does immune reconstitution contribute to ART-related bone loss?
New data from PrEP study shed light on adherence, bone mineral loss and resistance
